Coronary artery disease: Latest News, Top Stories & Analysis

NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced a new agreement with Japan’s Terumo Corporation (TYO: 4543) that grants Terumo a right of first refusal for the …

Regional

XyloCor Doses First Patient in Pivotal Gene Therapy Trial for Refractory Angina

July 15, 2025July 14, 2025 - by Timothy Alexander

KING OF PRUSSIA, PA — XyloCor Therapeutics has dosed the first patient in its Phase 2b EXACT-2 trial evaluating XC001 (encoberminogene rezmadenovec), a novel gene therapy designed to help patients …